Responding to FDA Form 483 Observations at the Conclusion of a Drug cGMP Inspection 

In March 2026, the FDA released guidance on how to respond to FDA Form 483 Observations at end of a drug cGMP inspection. The guidance details the process of responding to 483s including responsible parties, formatting of the responses, and  timeframes for submitting responses.